🔗 Share this article

This year's Nobel Prize in medical science has been granted for transformative discoveries that clarify how the body's defense network targets harmful infections while sparing the body's own cells.

Three esteemed scientists—from Japan Shimon Sakaguchi and American scientists Mary Brunkow and Dr. Ramsdell—share this accolade.

The research uncovered specialized "sentinels" within the immune system that eliminate malfunctioning defense cells capable of attacking the organism.

The discoveries are now paving the way for new therapies for autoimmune diseases and malignancies.

The laureates will share a monetary award worth 11 million SEK.

Crucial Discoveries

"The work has been decisive for comprehending how the body's defenses operates and the reason we do not all suffer from serious autoimmune diseases," commented the head of the award panel.

The trio's research address a fundamental mystery: How does the immune system defend us from countless invaders while keeping our own tissues intact?

Our immune system employs white blood cells that scan for signs of disease, even viruses and bacteria it has not met before.

Such cells employ detectors—called recognition units—that are produced by chance in countless combinations.

That gives the immune system the ability to combat a wide array of invaders, but the unpredictability of the mechanism unavoidably produces immune cells that can attack the body.

Security Guards of the Immune System

Researchers previously knew that a portion of these problematic defense cells were destroyed in the immune organ—where white blood cells develop.

This year's Nobel Prize honors the discovery of regulatory T-cells—described as the immune system's "peacekeepers"—which travel through the body to neutralize any defenders that attack the healthy cells.

We know that this process fails in self-attack conditions such as type-1 diabetes, multiple sclerosis, and rheumatoid arthritis.

A prize committee stated, "These discoveries have laid the foundation for a new field of research and spurred the development of new therapies, for instance for cancer and immune disorders."

In cancer, regulatory T-cells prevent the system from attacking the tumor, so studies are aimed at reducing their quantity.

In self-attack disorders, trials are exploring increasing regulatory T-cells so the body is no longer under attack. A similar method could also be effective in minimizing the chances of organ transplant failure.

Innovative Studies

Professor Shimon Sakaguchi, from Osaka University, performed tests on rodents that had their thymus removed, leading to autoimmune disease.

He showed that injecting defense cells from healthy animals could stop the illness—implying there was a mechanism for blocking defenders from harming the host.

Mary Brunkow, affiliated with the Institute for Systems Biology in Seattle, and Fred Ramsdell, now at Sonoma Biotherapeutics in a California city, were investigating an inherited autoimmune disease in mice and humans that led to the identification of a genetic factor critical for how T-regs operate.

"The pioneering research has revealed how the immune system is controlled by regulatory T cells, stopping it from mistakenly targeting the body's own tissues," commented a leading physiology specialist.

"This research is a striking illustration of how basic biological study can have broad implications for public health."